TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27832796

Group type: EXPERIMENTAL
Intervention: Antecedent hypertension
Number of subjects: 792

Group type: COMPARATOR
Intervention: No antecedent hypertension
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Both groups (hypertension and no hypertension)
Number of subjects: 792
Study: 25296147

Group type: EXPERIMENTAL
Intervention: Workplace Exercise (twice a week for 15 minutes over 10 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Workplace Exercise
Number of subjects: 30
Study: 22858219

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 51
Study: 21138634

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue therapy (early stage)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue therapy (middle stage)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (early stage)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (middle stage)
Number of subjects: 348
Study: 19910033

Group type: EXPERIMENTAL
Intervention: Omalizumab (75-375 mg sc, q2 or q4 wk)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study: 16546494

Group type: EXPERIMENTAL
Intervention: Oral medications (oral laxative, digestant, defoaming agent)
Number of subjects: 236

Group type: COMPARATOR
Intervention: NPO (nothing by mouth)
Number of subjects: 236
Study: 12694432

Group type: EXPERIMENTAL
Intervention: Immediate treatment (n=24)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delayed treatment (control, n=15)
Number of subjects: 39
Study: 11127527

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (endoscopy, chest radiography, abdominal ultrasound, CT pelvis)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Proposed follow-up concepts (risk-adaption)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Recommended German follow-up guideline
Number of subjects: 1054
Study: 9339980

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8382428

Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Closed glottis technique
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Open glottis technique
Number of subjects: 350

Group type: COMPARATOR
Intervention: Forced pushing
Number of subjects: 350
Study: 3535127

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg once daily
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg twice daily
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 2 tablets twice a day
Number of subjects: 528
Study: 31904681

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: 14-day triple therapy
Number of subjects: 103
Study: 29526681

Group type: EXPERIMENTAL
Intervention: Sleep duration categories (≤5.5, 6-6.5, 7-7.5, 8-8.5, and ≥9 hours)
Number of subjects: 2848

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 2848
Study: 27861400

Group type: EXPERIMENTAL
Intervention: 100-kVp protocol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: i-100-kVp protocol (100-kVp with hybrid iterative reconstruction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120-kVp protocol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: i-100-kVp protocol
Number of subjects: 100
Study: 24894651

Group type: EXPERIMENTAL
Intervention: EMD 1201081 0.32 mg/kg subcutaneously weekly plus cetuximab (combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab monotherapy (control)
Number of subjects: 0
Study: 21840917

Group type: EXPERIMENTAL
Intervention: Robot‐assisted therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dose‐matched active control therapy
Number of subjects: 20
Study: 19672708

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg + Rabeprazole 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg + Rabeprazole 40 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 15
Study: 18443775

Group type: EXPERIMENTAL
Intervention: FSTIR images
Number of subjects: 24

Group type: COMPARATOR
Intervention: FSE T2‐W images
Number of subjects: 24
Study: 15915935

Group type: EXPERIMENTAL
Intervention: Fenspiride treatment for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenspiride treatment
Number of subjects: 0
Study: 11821508

Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate cream (40 g per day)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Oral prednisone (0.5 mg/kg/day for moderate disease and 1 mg/kg/day for extensive disease)
Number of subjects: 341
Study: 9951426

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice a day for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pimozide (6 mg oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7752176

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg twice daily
Number of subjects: 23
Study: 1979363

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 926

Group type: COMPARATOR
Intervention: Formula only
Number of subjects: 926

Group type: COMPARATOR
Intervention: Formula plus breast milk
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Pasteurised donor milk
Number of subjects: 926

Group type: COMPARATOR
Intervention: Delayed enteral feeding in formula-fed infants
Number of subjects: 926

Group type: COMPARATOR
Intervention: Exclusive formula feeding
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Mortality in confirmed cases of necrotising enterocolitis
Number of subjects: 926
Study: 6993446

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Diazepam (18.6 mg/day)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 235
Study: 31532960

Group type: EXPERIMENTAL
Intervention: Maribavir (400, 800, or 1200 mg twice daily)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Valganciclovir (standard dose)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 161

Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 161
Study: 28056541

Group type: EXPERIMENTAL
Intervention: User-controlled text messaging intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no texting intervention)
Number of subjects: 64
Study: 26369656

Group type: EXPERIMENTAL
Intervention: PDA10
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eprex
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PDA10 and Eprex
Number of subjects: 30
Study: 23710811

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 62
Study: 21836117

Group type: EXPERIMENTAL
Intervention: Multi-risk social/cognitive intervention delivered by public health nurses (4 visits)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual and customary public health services (control group)
Number of subjects: 235
Study: 19767089

Group type: EXPERIMENTAL
Intervention: Methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Methotrexate 3.5 g/m(2) on day 1 (n=40)
Number of subjects: 79
Study: 17420402

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 331

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 331
Study: 14722639

Group type: EXPERIMENTAL
Intervention: Heparin-coated catheter
Number of subjects: 180

Group type: COMPARATOR
Intervention: Chlorhexidine and silver sulfadiazine-coated catheter
Number of subjects: 180
Study: 11478138

Group type: EXPERIMENTAL
Intervention: LH-RH agonist combined with tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: LH-RH agonist alone
Number of subjects: 0
Study: 9409569

Group type: EXPERIMENTAL
Intervention: Pringle maneuver (intermittent for 20 minutes with a 5-minute clamp-free interval)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no Pringle maneuver)
Number of subjects: 100
Study: 8009000

Group type: EXPERIMENTAL
Intervention: Pyrimethamine (Pyr)
Number of subjects: 554
Study: 3623815

Group type: EXPERIMENTAL
Intervention: Chronic fenfluramine
Number of subjects: 5
Study: 31420383

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) at 20 ppm administered into the CPB oxygenator for the duration of CPB
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Standard care (no NO)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)
Number of subjects: 1320
Study: 28117192

Group type: EXPERIMENTAL
Intervention: Psychotherapy for PTSD
Number of subjects: 321
Study: 25853743

Group type: EXPERIMENTAL
Intervention: Routine manual thrombectomy
Number of subjects: 10732

Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10732
Study: 23340885

Group type: EXPERIMENTAL
Intervention: myo-inositol plus 200 µg folic acid twice a day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (200 µg folic acid twice a day)
Number of subjects: 110
Study: 21830396

Group type: EXPERIMENTAL
Intervention: Supplement of 200kcal before endoscopic therapy (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No energy supplied (fasting group) before endoscopic therapy (n=18)
Number of subjects: 36
Study: 19880429

Group type: EXPERIMENTAL
Intervention: MEN11420 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MEN11420 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MEN11420 (both doses)
Number of subjects: 12
Study: 16309383

Group type: EXPERIMENTAL
Intervention: Intra-arterial TNF-alpha infusion
Number of subjects: 95

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 95
Study: 15639689

Group type: EXPERIMENTAL
Intervention: Tramadol LP 200 mg once daily
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 11157012

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil or cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by local therapy and radiotherapy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 70
Study: 9766106

Group type: EXPERIMENTAL
Intervention: Intraoral fluoride-releasing system (IFRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.1 percent neutral sodium fluoride gel in custom trays (Control)
Number of subjects: 0
Study: 7817812

Group type: EXPERIMENTAL
Intervention: ELISA for urinary deoxypyridinoline (Dpd)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Total Dpd by HPLC
Number of subjects: 402

Group type: COMPARATOR
Intervention: Normal adults (healthy individuals)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Children (healthy individuals)
Number of subjects: 402
Study: 3057063

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Propranolol (P)
Number of subjects: 65
Study: 31055729

Group type: EXPERIMENTAL
Intervention: Active information processing training (AIPT) (n = 49)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Post-control (n = 55)
Number of subjects: 205
Study: 28454553

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen used during daily activities for a 2-week period at an optimal flow rate determined by titration at screening visit.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ambulatory oxygen for a 2-week period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen
Number of subjects: 0
Study: 26408054

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program (exercise program 3 days/week, 90 min sessions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Family-based lifestyle and psycho-educational program (2 days/month)
Number of subjects: 160
Study: 24308693

Group type: EXPERIMENTAL
Intervention: Ingelvac PRRS MLV vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amervac PRRS vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pyrsvac‐183 vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Porcilis PRRS vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mock vaccination (Control)
Number of subjects: 120
Study: 21924624

Group type: EXPERIMENTAL
Intervention: Muscle vibration intervention (12×4 min daily at 100Hz, 0.3mm amplitude) during immobilization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ankle immobilization without vibration)
Number of subjects: 30
Study: 19812508

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 2616

Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP) with sit-ups
Number of subjects: 2616
Study: 16696910

Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsules (ZXKC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Probucol
Number of subjects: 112
Study: 15002082

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 775
Study: 11697808

Group type: EXPERIMENTAL
Intervention: 10 mg/day of alendronate, 0.50 microg/day of calcitriol, and 500 mg/day of calcium carbonate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.50 microg/day of calcitriol and 500 mg/day of calcium carbonate
Number of subjects: 40
Study: 9329411

Group type: EXPERIMENTAL
Intervention: Plastic tape
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pectin barrier
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrophilic gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no adhesive)
Number of subjects: 30
Study: 7608850

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium during the first 10 post-operative days
Number of subjects: 24

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 3043111

Group type: EXPERIMENTAL
Intervention: MCNU
Number of subjects: 77

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 77
Study: 29143156

Group type: EXPERIMENTAL
Intervention: Participants preferred greater social distance from a person with psychosis than a person with depression.
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Beliefs that PPSD were dangerous increased social distance.
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Familiarity with PPSD and belief in their recovery reduced social distance.
Number of subjects: 960
Study: 28785895

Group type: EXPERIMENTAL
Intervention: TIVA or inhalational general anesthesia
Number of subjects: 59
Study: 26206144

Group type: EXPERIMENTAL
Intervention: Annual mammographic screening from age 40 years
Number of subjects: 160921

Group type: COMPARATOR
Intervention: Usual medical care (invited for screening at age 50 years and every 3 years thereafter)
Number of subjects: 160921
Study: 24086114

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 755

Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Usual Care
Number of subjects: 755
Study: 20499061

Group type: EXPERIMENTAL
Intervention: Hip resurfacing for rheumatoid arthritis
Number of subjects: 178

Group type: COMPARATOR
Intervention: Osteoarthritis group
Number of subjects: 178
Study: 19073976

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg per day)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Placebo (for aspirin group)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Resistant starch (30 g per day)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Placebo (for resistant starch group)
Number of subjects: 1071
Study: 22437997

Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DuraPrep (0.7% available iodine and 74% isopropyl alcohol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ChloraPrep
Number of subjects: 100

Group type: COMPARATOR
Intervention: DuraPrep
Number of subjects: 100
Study: 15662112

Group type: EXPERIMENTAL
Intervention: Oral suspension of granisetron (2 mg) and dexamethasone (16 mg for highly emetogenic chemotherapy, 4 mg for moderately emetogenic chemotherapy)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Quality of life parameters
Number of subjects: 43
Study: 12662126

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) intravenously once weekly for 4 weeks
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) intravenously plus CHOP chemotherapy
Number of subjects: 399

Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 399
Study: 10434816

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 7495042

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 345

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 345

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 345

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 345
Study: 2079176

Group type: EXPERIMENTAL
Intervention: Conservative modified MO and DO preparations with glass-ionomer liner
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional MO and DO preparations with glass-ionomer liner
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conservative modified MO and DO preparations with calcium hydroxide liner
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional MO and DO preparations with calcium hydroxide liner
Number of subjects: 28
Study: 381092

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg four times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12121503

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Rabeprazole regimen in homozygous extensive metabolizer genotype
Number of subjects: 183
Study: 29482528

Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin + saxagliptin)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saxagliptin monotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Saxagliptin, metformin, and combination treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Saxagliptin and metformin treatments
Number of subjects: 75
Study: 26772778

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both VCV and PCV
Number of subjects: 52
Study: 25415673

Group type: EXPERIMENTAL
Intervention: Augmented group (1mL of polymethylmethacrylate cement injected through the screw)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonaugmented group (no cement injection)
Number of subjects: 14
Study: 22409966

Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nasal antiseptic ointment (oxytetracycline hydrochloride‐polymyxin B sulfate)
Number of subjects: 100
Study: 20032785

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 883

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 883

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 883
Study: 19100932

Group type: EXPERIMENTAL
Intervention: 30 mg of ondansetron (Group O)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 30 mg of ondansetron plus 20 mg of prochlorperazine (Group OP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antiemetic (Group C; control group)
Number of subjects: 150
Study: 16837133

Group type: EXPERIMENTAL
Intervention: LPS/LPS homozygotes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APS/APS homozygotes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APS/HPS heterozygotes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: val(158)met genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COMT haplotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: temporal summation of heat pain
Number of subjects: 0
Study: 12771740

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 mg prostaglandin E1 within the first 3 months (group 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intracavernous injection of 20 mg prostaglandin E1 at 4 to 12 months (group 2)
Number of subjects: 73
Study: 10758084

Group type: EXPERIMENTAL
Intervention: Computerized list method of recruitment
Number of subjects: 187

Group type: COMPARATOR
Intervention: Manual recording method of recruitment
Number of subjects: 187
Study: 8844449

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1385902

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Depo‐Medrol 80 mg/ml)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bupivacaine (Marcaine .5% 1.5 ml)
Number of subjects: 25